Cargando…

Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice

PURPOSE: Accumulating evidence suggests that not all cancer chemotherapy patients who receive first-cycle pegfilgrastim prophylaxis continue to receive it in subsequent cycles and that these patients may be subsequently at higher risk of febrile neutropenia (FN). Additional evidence from US clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weycker, Derek, Li, Xiaoyan, Barron, Rich, Li, Yanli, Reiner, Maureen, Kartashov, Alex, Figueredo, Jacqueline, Tzivelekis, Spiros, Garcia, Jacob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846701/ https://www.ncbi.nlm.nih.gov/pubmed/26670915 http://dx.doi.org/10.1007/s00520-015-3039-4

Ejemplares similares

Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
por: Weycker, Derek, et al.
Publicado: (2015)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
por: Cerchione, Claudio, et al.
Publicado: (2021)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
por: Lee, Jihyoun, et al.
Publicado: (2018)

Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL Study
por: Jurczak, Wojciech, et al.
Publicado: (2015)

Pegfilgrastim Versus Filgrastim for Primary Prophylaxis of Febrile Neutropenia in Patients with non-Hodgkin’s Lymphoma: A Cost-Effectiveness Study
por: Ravangard, Ramin, et al.
Publicado: (2017)

A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis
por: Mahtani, Reshma L., et al.
Publicado: (2022)

Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study
por: Weycker, Derek, et al.
Publicado: (2019)

Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil
por: Ohkura, Yu, et al.
Publicado: (2019)

Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis
por: Weycker, Derek, et al.
Publicado: (2014)

The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis
por: Li, Edward, et al.
Publicado: (2021)

Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice
por: Averin, Ahuva, et al.
Publicado: (2020)

Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type
por: Alrawashdh, Neda, et al.
Publicado: (2022)

Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study
por: Wang, Ching-Yu, et al.
Publicado: (2023)

Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study
por: Jeon, Youngwoo, et al.
Publicado: (2023)

Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population
por: Wang, Ching-Yu, et al.
Publicado: (2022)

Clinical practice in secondary prophylaxis and management of febrile neutropenia in Poland: results of the febrile neutropenia awareness project
por: Wojtukiewicz, Marek, et al.
Publicado: (2014)

An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer
por: Lee, Anbok, et al.
Publicado: (2023)

Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases
por: Weycker, Derek, et al.
Publicado: (2013)

A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices
por: Rifkin, Robert M., et al.
Publicado: (2022)

Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
por: Gebremariam, Girma Tekle, et al.
Publicado: (2022)

COVID-19 Prevention Guidance and the Incidence of Febrile Neutropenia in Patients with Breast Cancer Receiving TAC Chemotherapy with Prophylactic Pegfilgrastim
por: Gwak, Hongki, et al.
Publicado: (2022)

Safety and tolerability of Peg-grafeel(™), a pegfilgrastim, for the prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India
por: Talwar, Vineet, et al.
Publicado: (2017)

Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience
por: Cerchione, Claudio, et al.
Publicado: (2016)

Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
por: Wojtukiewicz, Marek, et al.
Publicado: (2014)

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations
por: Aapro, Matti, et al.
Publicado: (2017)

Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia
por: Hodgson-Viden, Heather, et al.
Publicado: (2005)

Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy
por: Wang, Xiao Jun, et al.
Publicado: (2016)

Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study
por: Jeong, Seong Hyun, et al.
Publicado: (2022)

Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin’s lymphoma in European and Australian clinical practice
por: Weycker, Derek, et al.
Publicado: (2012)

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
por: Akpo, Esse I. H., et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma
por: Fust, Kelly, et al.
Publicado: (2016)

Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update
por: Villafuerte-Gutierrez, Paola, et al.
Publicado: (2014)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
por: Otremba, Burkhard, et al.
Publicado: (2018)

Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
Publicado: (2021)

Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices
por: Morrison, Vicki A., et al.
Publicado: (2007)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
por: Innocenti, Rolando, et al.
Publicado: (2018)

Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy
por: Li, Yanli, et al.
Publicado: (2016)

Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines
por: Naeem, Doaa, et al.
Publicado: (2018)

Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma
por: Kim, Do Young, et al.
Publicado: (2022)

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy
por: Kosaka, Yoshimasa, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0ks2tbdhi8jjj9umqqfsokccp2